Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 6/20 | 0.57 |
| ▸ | MAOA | P21397 | 3/20 | 0.57 |
| ▸ | MMP1 | P03956 | 2/20 | 0.57 |
| ▸ | MMP2 | P08253 | 2/20 | 0.57 |
| ▸ | MMP9 | P14780 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | CDK9 | P50750 | 1/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.56 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6302448 | 0.81 | MMP1 (0.73) | TGM2CYP1A2NPSR1MAOBMAOA | |
| SCHEMBL9840923 | 0.81 | MMP1 (0.73) | TGM2CYP1A2NPSR1MAOBMAOA | |
| SCHEMBL6302452 | 0.81 | MMP1 (0.73) | TGM2CYP1A2NPSR1MAOBMAOA | |
| SCHEMBL2900749 | 0.79 | TGM2 (0.65) | TGM2CYP1A2NPSR1MAOBMAOA | |
| SCHEMBL725250 | 0.79 | TGM2 (0.65) | TGM2CYP1A2NPSR1MAOBMAOA | |
| SCHEMBL11603085 | 0.78 | TGM2 (0.59) | TGM2CYP1A2NPSR1MAOBMAOA | |
| SCHEMBL11601122 | 0.78 | TGM2 (0.64) | TGM2CYP1A2NPSR1MAOBMAOA | |
| SCHEMBL9080645 | 0.77 | TGM2 (0.63) | TGM2CYP1A2NPSR1MAOBMAOA | |
| SCHEMBL81209 | 0.77 | TGM2 (1.00) | TGM2CYP1A2NPSR1MAOBMAOA | |
| SCHEMBL2664164 | 0.77 | TGM2 (0.63) | TGM2CYP1A2NPSR1MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0813525-B9 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LAB (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6686364-B2 | 4-HYDROXY-3-((3,5-DIFLUORO-6-(3 -DIMETHYLAMINOCARBONYLPHENOXY)-4-(2-METHOXY-4-CARBOXYPHENOXY) PYRIDIN-2-YL)OXY)BENZAMIDINE, FOR EXAMPLE; FACTOR XA INHIBITORS | BERLEX LABORATORIES, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-0813525-B1 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LAB (US) | 2003-10-01 | — | — | EP | disclosed |
| US-6479485-B2 | 4-HYDROXY-3-((3,4-DIFLUORO-6-(3 -DIMETHYLAMINOCARBONYLPHENOXY)-4-(2-METHOXY-4-CARBOXYPHENOXY) PYRIDIN-2-YL)OXY)BENZAMIDINE, FOR EXAMPLE; INHIBITION OF BLOOD COAGGULATION FACTOR XA | BERLEX LABORATORIES, INC. | 2002-11-12 | — | — | US | disclosed |
| US-6465459-B2 | INHIBIT THE ENZYME, FACTOR XA | BERLEX LABORATORIES, INC. | 2002-10-15 | — | — | US | disclosed |
| US-20020035109-A1 | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. | 2002-03-21 | — | — | US | disclosed |
| US-20020032223-A1 | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. | 2002-03-14 | — | — | US | disclosed |
| US-20020028820-A1 | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. | 2002-03-07 | — | — | US | disclosed |
| US-6350746-B1 | FACTOR XA ENZYME INHIBITORS | BERLEX LABORATORIES, INC. | 2002-02-26 | — | — | US | disclosed |
| US-6306884-B1 | ANTICOAGULANTS AND BLOOD COAGULATION FACTOR | BERLEX LABORATORIES, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6034103-A | THROMBOSIS THERAPY | BERLEX LABORATORIES, INC. (US) | 2000-03-07 | — | — | US | disclosed |
| US-6004981-A | HUMAN FACTOR XA INHIBITORS | BERLEX LABORATORIES, INC. | 1999-12-21 | — | — | US | disclosed |
| US-5889005-A | Benzamidine derivatives and their use for treating thrombotic diseases | BERLEX LABORATORIES, INC. (US) | 1999-03-30 | — | — | US | disclosed |
| US-5883100-A | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5877181-A | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0813525-A1 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5691364-A | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1997-11-25 | — | — | US | disclosed |
| WO-1996028427-A1 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032223-A1 | Benzamidine derivatives and their use as anti-coagulants | SERPINC1, HABP2, SERPINE1 | TGM2 530/4885CYP1A2 653/4885NPSR1 4439/4885 |
| US-20020028820-A1 | Benzamidine derivatives and their use as anti-coagulants | SERPINC1, HABP2, SERPINE1 | TGM2 530/4885CYP1A2 653/4885NPSR1 4439/4885 |
| US-20020035109-A1 | Benzamidine derivatives and their use as anti-coagulants | SERPINC1, HABP2, SERPINE1 | TGM2 507/4885CYP1A2 689/4885NPSR1 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.